Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
08/2005
08/10/2005CN1652786A Fluorinated 4-azasteroid derivatives as androgen receptor modulators
08/10/2005CN1652782A Nicotinamide derivatives useful as PDE4 inhibitors
08/10/2005CN1652779A Treatment of chemokine mediated diseases
08/10/2005CN1652770A Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
08/10/2005CN1652761A Preventive or therapeutic agent for kidney disease
08/10/2005CN1651919A CD154 blockade monoclone antibody use for inhibiting rejection of insulin producing tissue transplantation
08/10/2005CN1651466A Sulphatization derivative of polysaccharide, its preparation method and use
08/10/2005CN1651457A Nucleotide sequences of HIV-1 group (or subgroup) o retroviral antigens
08/10/2005CN1651431A Inhibitors of alpha L beta 2 mediated cell adhesion
08/10/2005CN1651071A CD154 blockade therapy for therapeutic protein inhibitor syndrome
08/10/2005CN1651070A Health care product having immune regulating and antimutation action
08/10/2005CN1651055A Natural life beneficial Chinese medicine
08/10/2005CN1651041A Brazil mushroom soluble small molecular extract, its preparation technology and use
08/10/2005CN1650996A Medicinal composition, its preparation method and application
08/10/2005CN1650923A Medicinal composition for treating theumalism and rheumatism diseases
08/10/2005CN1214043C Humanized antibodies to gamma-interferon
08/10/2005CN1214039C 3-nitrogen-6,7-dioxygen steroids and uses thereof
08/10/2005CN1214022C Vitamin D analogues
08/10/2005CN1214014C HIV inhibiting pyrimidine derivatives
08/10/2005CN1214006C Novel vitamin D derivatives with cyclopropyl rings in lateral chains, its production method and intermediate and utilization thereof for producing medicaments
08/10/2005CN1213980C Vitamin D analogues
08/10/2005CN1213767C Topical compositions comprising ascomycins
08/10/2005CN1213752C Treating allergic and inflammatory diseases
08/10/2005CN1213746C Immunopotentiatory agents and physiologically acceptable salts thereof
08/10/2005CN1213742C Pharmaceutical control of inflammation
08/10/2005CN1213733C Method of preparing stable suspension of insoluble microparticles
08/09/2005US6927234 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity
08/09/2005US6927230 Triazole derivatives
08/09/2005US6927228 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation
08/09/2005US6927227 Heterocyclic containing biphenyl aP2 inhibitors and method
08/09/2005US6927222 Compounds
08/09/2005US6927219 Secondary amides such as N-Adamantan-1-methyl-2-chloro-5-(3,5-dioxo-4,5-dihydro-3H- (1,2,4)triazin-2-yl)-benzamide used as antagonists for biological receptors; antiinflammatiory, anticarcinogenic or antiischemic agents
08/09/2005US6927218 Aryl N-cyanoguanidines and methods related thereto
08/09/2005US6927208 for the treatment and prevention of AIDS
08/09/2005US6926899 Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test
08/09/2005US6926898 Albumin fusion proteins
08/09/2005US6926893 Multi-stage cascade boosting vaccine
08/09/2005CA2310627C Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
08/09/2005CA2189705C Use of flupirtine for the prophylaxis and therapy of diseases associated with an impairment of the haematopoetic cell system
08/09/2005CA2168012C Polymeric matrices and their uses in pharmaceutical compositions
08/09/2005CA2136952C Preparation for activation of natural killer cells (nk-cells), said preparation containing interferon-– and histamine, serotonin, amines or substances with corresponding receptor activity
08/09/2005CA2135278C Peptide for stimulation of cytotoxic t lymphocytes specific for hepatitis c virus
08/09/2005CA2095659C Heteroatoms-containing tricyclic compounds
08/04/2005WO2004007457A3 Substituted benzylamine derivatives and methods of use
08/04/2005US20050171354 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for prophylaxis of cardiovascular disorders
08/04/2005US20050171353 Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5)
08/04/2005US20050171345 Pteridine compounds for the treatment of psoriasis
08/04/2005US20050171286 Copolymer-1 improvements in compositions of copolymers
08/04/2005US20050171188 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
08/04/2005US20050171187 Making intermediates to alpha-ethyl-2-oxo-1-pyrrolidine acetamide, also referred to as levetiracetam an antihypoxic agent and antiischemic agent; by reduction via catalytic hydrogenation of an alkenyl intermediate
08/04/2005US20050171183 Indole-type inhibitors of p38 kinase
08/04/2005US20050171178 Exo-1-methyl-1H-imidazole-4-sulfonic acid {3-[6-ethyl-3-(2-hydroxy-indan-2-ylmethyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-phenyl}-amide; opioid receptors (mu, kappa and delta) antagonists; not substrate of the variable enzyme CYP2D6; addiction to an opiates, alcohol; obesity
08/04/2005US20050171174 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
08/04/2005US20050171163 MCP-1 receptor antagonists and methods of use thereof
08/04/2005US20050171153 Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
08/04/2005US20050171149 antioxidant properties and peroxisome proliferator activated receptors (PPAR) alpha and PPAR gamma activator properties; cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms, neurodegenerative, and skin disorders
08/04/2005US20050171143 selective Chemoattractant receptor-homologous molecule expressed on Th2 cells ( CRTH2 receptor) antagonist; activities for eosinphil and basophil infiltration; indol/carbazol-sulfonamide derivatives; antiallergenic agent; asthma, allergic rhinitis and dermatitis, polyarteritis, autoimmune disease
08/04/2005US20050171129 Polycyclic guanine derivative phosphodiesterase V inhibitors
08/04/2005US20050171128 Pyrrolo[2,3-d]pyrimidine compounds
08/04/2005US20050171125 Novel alkoxypyridine-derivatives
08/04/2005US20050171122 Mitotic kinesin inhibitors
08/04/2005US20050171119 Two-layer tablet of efletirizine (2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid) containing an immediate release layer and a time-release layer for once daily dosage; antihistamine, bronchodilator and antispasmodic agent
08/04/2005US20050171117 Preparation of pharmaceutical salts
08/04/2005US20050171111 E.g., 4-[[5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]hydroxymethyl]-1H-imidazol-1-yl]methyl]-benzonitrile; prevents the membrane attachment of p21ras and blocks the aberrant growth of ras-transformed tumors
08/04/2005US20050171101 Neurodegenerative diseases; diseases ascribed by NMDA- and NO-induced neurotoxicity ; ischemia; antiinflammatory; anticancer; antidiabetic; 2-{3-[4-Phenyl-3,6-dihydro-1(2H)-pyridyl]propyl}-6(5H)-phenanthridinone
08/04/2005US20050171096 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
08/04/2005US20050171094 Pyrrolopyrimidine derivatives
08/04/2005US20050171092 Chemical compounds
08/04/2005US20050171091 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
08/04/2005US20050171075 Substitued 19-nor-cholestenes; antineoplastic agents, wound healing agents, antiinflammatory agents; autoimmune diseases, transplant rejection inhibition, hyperplasia, graft versus host disease; increased cell growth modulation and differentiation, low calcemic activity
08/04/2005US20050171068 Novel 4-dedimethylaminotetracycline derivatives
08/04/2005US20050171047 Immunostimulatory nucleic acid molecules
08/04/2005US20050170451 Human type antihuman ige receptor antibody and fragment
08/04/2005US20050170436 Inducing specific B cell anergy to an immunogen comprising a conjugate of a nonimmunogenic valency platform molecule and an analog of the immunogen that (a) binds specifically to B cells to which the immunogen binds and (b) lacks the T cell epitope(s) of the immunogen
08/04/2005US20050170355 Mixture of a nucleic acid and a chitosan with branching groups attached to the amino group, selected from alkyl groups with 2 or more carbon atoms, monosaccharides, oligosaccharides or polysaccharides; gene therapy, genetic vaccines, antisense therapy, anticarcinogenic agents, autoimmune diseases
08/04/2005US20050169993 Sustained-release formulation
08/04/2005US20050169983 Chewable soft capsule
08/04/2005US20050169923 monoclonal antibody prevents the growth or differentiation of the B cell; secreted by the hybridoma; therapy of autoimmune diseases, sytematic lupus erythematosus, primary biliary cirrhosis, and idiopathic thrombocytopenic purpura; biodrug
08/04/2005US20050169922 drug screening for compounds that enhance or suppress killer T cell activity by contacting killer T cells which express biliary glycoprotein with a compound that binds biliary glycoprotein and determining the cytotoxicity or proliferation of the killer T cells relative to a control
08/04/2005US20050169918 selectively targeting; screening an effect of a Chemokine receptor (CCR4) modulating agent; adjusting the adhesion of T cells to endothelial cells; treating inflammatory skin disease; side effect reduction without affecting on other cells
08/04/2005US20050169913 Administering a monoclonal antibody or enzyme inhibitor of prothrombinase; therapeutic treatment of bacterial and viral infections, allograft and xenograft rejection, cancer, glomerulonephritis, gastrointestinal disorders and fetal loss; inhibiting gene expression of prothrombinase
08/04/2005US20050169889 Immunogenic agent therapy using plasmapheresis or exchange transfusion
08/04/2005US20050169884 Administering an hematopoietic colony stimulating factors of sargramostim; Crohn's Disease
08/04/2005US20050169853 Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with Porphyromonas gingivalis
08/04/2005CA2553551A1 Methods and compositions for determining a graft tolerant phenotype in a subject
08/04/2005CA2553513A1 N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
08/04/2005CA2553221A1 Folate conjugates and complexes
08/04/2005CA2552763A1 Method of treating type iii hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
08/04/2005CA2495839A1 Anti-photoaging cosmeceutical composition
08/03/2005EP1559786A1 Membrane protein originating in mast cells
08/03/2005EP1559780A1 Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity
08/03/2005EP1559726A2 Growth differentiation factor-10
08/03/2005EP1559710A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use
08/03/2005EP1559709A1 Heterocycle-containing carboxylic acid derivative and drug containing the same
08/03/2005EP1559708A1 2,2-DI-SUBSTITUTED 1a,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE
08/03/2005EP1559428A1 Receptor regulator
08/03/2005EP1559425A1 Peroral preparation for prevention of or treatment for atopic dermatitis
08/03/2005EP1559424A2 The use of inhibitors of the renin-angiotensin system
08/03/2005EP1559422A1 Receptor function controlling agent
08/03/2005EP1558740A2 Recombinant protein variants
1 ... 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 ... 1172